Emerging Markets Solid For Novartis But Slower In 2015?
This article was originally published in PharmAsia News
Novartis has reported generally strong growth in emerging markets in the calendar fourth quarter and 2014, but says a range of factors may to contribute to a likely slowdown this year.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.